Jonine L Bernstein1, Patrick Concannon2. 1. a Department of Epidemiology and Biostatistics , Memorial Sloan Kettering Cancer Center , New York , NY , U.S.A. 2. b Genetics Institute and Department of Pathology, Immunology and Laboratory Medicine , University of Florida , Gainesville , FL , U.S.A.
Abstract
PURPOSE: It was first suggested more than 40 years ago that heterozygous carriers for the human autosomal recessive disorder Ataxia-Telangiectasia (A-T) might also be at increased risk for cancer. Subsequent studies have identified the responsible gene, Ataxia-Telangiectasia Mutated (ATM), characterized genetic variation at this locus in A-T and a variety of different cancers, and described the functions of the ATM protein with regard to cellular DNA damage responses. However, an overall model of how ATM contributes to cancer risk, and in particular, the role of DNA damage in this process, remains lacking. This review considers these questions in the context of contralateral breast cancer (CBC). CONCLUSIONS: Heterozygous carriers of loss of function mutations in ATM that are A-T causing, are at increased risk of breast cancer. However, examination of a range of genetic variants, both rare and common, across multiple cancers, suggests that ATM may have additional effects on cancer risk that are allele-dependent. In the case of CBC, selected common alleles at ATM are associated with a reduced incidence of CBC, while other rare and predicted deleterious variants may act jointly with radiation exposure to increase risk. Further studies that characterize germline and somatic ATM mutations in breast cancer and relate the detected genetic changes to functional outcomes, particularly with regard to radiation responses, are needed to gain a complete picture of the complex relationship between ATM, radiation and breast cancer.
PURPOSE: It was first suggested more than 40 years ago that heterozygous carriers for the humanautosomal recessive disorderAtaxia-Telangiectasia (A-T) might also be at increased risk for cancer. Subsequent studies have identified the responsible gene, Ataxia-Telangiectasia Mutated (ATM), characterized genetic variation at this locus in A-T and a variety of different cancers, and described the functions of the ATM protein with regard to cellular DNA damage responses. However, an overall model of how ATM contributes to cancer risk, and in particular, the role of DNA damage in this process, remains lacking. This review considers these questions in the context of contralateral breast cancer (CBC). CONCLUSIONS: Heterozygous carriers of loss of function mutations in ATM that are A-T causing, are at increased risk of breast cancer. However, examination of a range of genetic variants, both rare and common, across multiple cancers, suggests that ATM may have additional effects on cancer risk that are allele-dependent. In the case of CBC, selected common alleles at ATM are associated with a reduced incidence of CBC, while other rare and predicted deleterious variants may act jointly with radiation exposure to increase risk. Further studies that characterize germline and somatic ATM mutations in breast cancer and relate the detected genetic changes to functional outcomes, particularly with regard to radiation responses, are needed to gain a complete picture of the complex relationship between ATM, radiation and breast cancer.
Entities:
Keywords:
ATM; Ataxia-Telangiectasia; allelic heterogeneity; breast cancer; radiation therapy
Authors: T Uziel; K Savitsky; M Platzer; Y Ziv; T Helbitz; M Nehls; T Boehm; A Rosenthal; Y Shiloh; G Rotman Journal: Genomics Date: 1996-04-15 Impact factor: 5.736
Authors: Marilyn Stovall; Susan A Smith; Bryan M Langholz; John D Boice; Roy E Shore; Michael Andersson; Thomas A Buchholz; Marinela Capanu; Leslie Bernstein; Charles F Lynch; Kathleen E Malone; Hoda Anton-Culver; Robert W Haile; Barry S Rosenstein; Anne S Reiner; Duncan C Thomas; Jonine L Bernstein Journal: Int J Radiat Oncol Biol Phys Date: 2008-06-14 Impact factor: 7.038
Authors: Simon A Forbes; David Beare; Prasad Gunasekaran; Kenric Leung; Nidhi Bindal; Harry Boutselakis; Minjie Ding; Sally Bamford; Charlotte Cole; Sari Ward; Chai Yin Kok; Mingming Jia; Tisham De; Jon W Teague; Michael R Stratton; Ultan McDermott; Peter J Campbell Journal: Nucleic Acids Res Date: 2014-10-29 Impact factor: 16.971
Authors: Brittany L Murphy; Min Yi; Banu K Arun; Angelica M Gutierrez Barrera; Isabelle Bedrosian Journal: Ann Surg Oncol Date: 2020-07-27 Impact factor: 5.344
Authors: Lindsay M Morton; Danielle M Karyadi; Stephen W Hartley; Megan N Frone; Joshua N Sampson; Rebecca M Howell; Joseph P Neglia; Michael A Arnold; Belynda D Hicks; Kristine Jones; Bin Zhu; Casey L Dagnall; Eric Karlins; Meredith S Yeager; Wendy M Leisenring; Yutaka Yasui; Lucie M Turcotte; Susan A Smith; Rita E Weathers; Jeremy Miller; Byron S Sigel; Diana M Merino; Amy Berrington de Gonzalez; Smita Bhatia; Leslie L Robison; Margaret A Tucker; Gregory T Armstrong; Stephen J Chanock Journal: JCO Precis Oncol Date: 2020-08-21
Authors: Katharine A Yao K; Jacob Clifford; Shuwei Li; Holly LaDuca; Peter Hulick; Stephanie Gutierrez; Mary Helen Black Journal: JNCI Cancer Spectr Date: 2020-10-26
Authors: Fabienne Lesueur; Douglas F Easton; Anne-Laure Renault; Sean V Tavtigian; Jonine L Bernstein; Zsofia Kote-Jarai; Rosalind A Eeles; Dijana Plaseska-Karanfia; Lidia Feliubadaló; Banu Arun; Natalie Herold; Beatrix Versmold; Rita Katharina Schmutzler; Tú Nguyen-Dumont; Melissa C Southey; Leila Dorling; Alison M Dunning; Paola Ghiorzo; Bruna Samia Dalmasso; Eve Cavaciuti; Dorothée Le Gal; Nicholas J Roberts; Mev Dominguez-Valentin; Matti Rookus; Alexander M R Taylor; Alisa M Goldstein; David E Goldgar; Dominique Stoppa-Lyonnet; Nadine Andrieu Journal: Fam Cancer Date: 2021-06-14 Impact factor: 2.375
Authors: Katharine Yao; Richard Bleicher; Meena Moran; Cecilia Chang; Jill Dietz; Vered Stearns; James Connolly; Terry Sarantou; Scott Kurtzman Journal: Cancer Med Date: 2020-03-11 Impact factor: 4.452